BIO (Life Sciences Tools & Services) Stock Valuation & Fair Value Significantly overvalued
BIO (Life Sciences Tools & Services) trades at a blended P/E of 34.9, about 9% above its historical normal valuation, with a forward growth estimate of 5.8% and a PEG of 6.05. Analysts' one-year estimates have been hit 18% of the time.
Valuation flags
- High PEG (6.1x)
Frequently asked questions
Is BIO overvalued?
At a blended P/E of 34.9 versus its historical normal P/E of 32.1, BIO trades about 9% above its typical valuation, with a PEG of 6.05 on 5.8% forward growth. tickerseer currently rates it significantly overvalued.
What is BIO's fair value and PEG?
BIO trades at a blended P/E of 34.9 against a historical normal P/E of 32.1, a PEG of 6.05, and a forward growth estimate of 5.8%.
Has tickerseer's rating of BIO changed?
tickerseer's rating has been significantly overvalued since 2026-07-31.
Industry: Life Sciences Tools & Services. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.